Home > Insider Trading > Filing (0001104659-19-037459)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1744659	Akero Therapeutics Inc.	AKRO	()	DE

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1687880	Versant Venture Capital Vi, L.p.	C/O Akero Therapeutics, Inc. 170 Harbor Way, 3Rd Floor South San Francisco CA 94080		No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2019-06-24	3,469,759	$0.00	3,469,759	No	4	C	Direct
Common Stock	Acquisiton	2019-06-24	235,099	$0.00	3,704,858	No	4	C	Direct
Common Stock	Acquisiton	2019-06-24	400,000	$16.00	4,104,858	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	C	Direct
No	4	C	Direct
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2019-06-24	10,666,667	$0.00	3,469,759	$0.00
Common Stock	Series B Preferred Stock	Disposition	2019-06-24	722,737	$0.00	235,099	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Direct
0			No	4	C	Direct

Footnotes

Represents the total number of shares of common stock received by Versant Venture Capital VI, L.P. ("Versant VI") upon the conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering.
All series of preferred stock automatically converted into the Issuer's common stock on a 3.07418-for-one basis upon the closing of the Issuer's initial public offering on June 24, 2019 and had no expiration date.
Represents the total number of shares of common stock received by Versant VI upon the conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering.
These shares are owned directly by Versant VI. Versant Ventures VI GP, LP ("Versant GP LP") is the general partner of Versant VI and Versant Ventures VI GP-GP, LLC ("Versant GP LLC") is the general partner of Versant GP LP and the ultimate general partner of Versant VI.
On June 24, 2019, Versant VI purchased 400,000 shares of common stock of the Issuer at a price of $16.00 per share pursuant to an underwritten public offering.